ADMA logo

ADMA
Adma Biologics Inc

20,737
Mkt Cap
$1.97B
Volume
3.72M
52W High
$22.37
52W Low
$7.21
PE Ratio
12.20
ADMA Fundamentals
Price
$8.27
Prev Close
$8.50
Open
$8.48
50D MA
$11.12
Beta
1.29
Avg. Volume
5.83M
EPS (Annual)
$0.60
P/B
4.92
Rev/Employee
$788,520.87
$4,459.32
Loading...
Loading...
News
all
press releases
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADMA Biologics, Inc. - ADMA
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADMA Biologics, Inc. - ADMA INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADMA...
PR Newswire·1d ago
News Placeholder
More News
News Placeholder
Here's What Analysts Think About ADMA Biologics (ADMA)
Here's What Analysts Think About ADMA Biologics (ADMA...
Yahoo! Finance: News·2d ago
News Placeholder
Is Adma Biologics (ADMA) a Buy as Wall Street Analysts Look Optimistic?
The average brokerage recommendation (ABR) for Adma Biologics (ADMA) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?
Zacks·2d ago
News Placeholder
New Strong Sell Stocks for May 14th
ADMA, AMTB and APOG have been added to the Zacks Rank #5 (Strong Sell) List on May 14th, 2026.
Zacks·2d ago
News Placeholder
New Strong Sell Stocks for May 11th
ADMA, APTV and ASTE have been added to the Zacks Rank #5 (Strong Sell) List on May 11th, 2026.
Zacks·5d ago
News Placeholder
Rosen Law Firm Encourages ADMA Biologics, Inc. Investors to Inquire About Securities Class Action Investigation - ADMA
Rosen Law Firm Encourages ADMA Biologics, Inc. Investors to Inquire About Securities Class Action Investigation - ADMA Rosen Law Firm Encourages ADMA Biologics, Inc. Investors to Inquire About...
PR Newswire·8d ago
News Placeholder
ADMA Q1 EPS Jumps 73% Y/Y, Revenues Slip, 2026 View Down
ADMA cuts its 2026 outlook after Q1 revenues slip amid IG market pressure, though Asceniv demand and margins stay strong.
Zacks·9d ago
News Placeholder
ADMA Tumbles On Slashed Outlook As Short-Seller Aftermath Meets Competitive Headwinds
In a statement, President and CEO Adam Grossman acknowledged near-term challenges but emphasized underlying strength in its therapy ASCENIV’s demand.
Stocktwits·9d ago
News Placeholder
ADMA Biologics (NASDAQ:ADMA) Issues Quarterly Earnings Results, Meets Expectations
ADMA Biologics (NASDAQ:ADMA - Get Free Report) issued its quarterly earnings results on Wednesday. The biotechnology company reported $0.19 earnings per share for the quarter, meeting analysts' consensus estimates of $0.19. ADMA Biologics had a net margin of 28.80% and a return on equity of 37.52...
MarketBeat·9d ago
News Placeholder
ADMA Biologics Q1 Earnings Call Highlights
ADMA Biologics (NASDAQ:ADMA) executives said the company delivered earnings growth and margin expansion in the first quarter of 2026 despite essentially flat total revenue, as strong demand for its immunoglobulin product ASCENIV offset a steep decline in standard IG product BIVIGAM amid what managem...
MarketBeat·9d ago
<
1
2
...
>

Latest ADMA News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.